The influence of proton pump inhibitors on the antiplatelet potency of clopidogrel evaluated by 5 different platelet function tests

Journal of Cardiovascular Pharmacology

Volumn 56, Issue 5, 2010, Pages 532-539

  Gremmel, Thomas ^a   Steiner, Sabine ^a   Seidinger, Daniela ^a   Koppensteiner, Renate ^a   Panzer, Simon ^a   Kopp, Christoph W ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

clopidogrel; platelet function tests; proton pump inhibitors

Indexed keywords

ACETYLSALICYLIC ACID; ADENOSINE DIPHOSPHATE; CLOPIDOGREL; ESOMEPRAZOLE; LANSOPRAZOLE; OMEPRAZOLE; PANTOPRAZOLE; PURINERGIC P2Y12 RECEPTOR; VASODILATOR STIMULATED PHOSPHOPROTEIN;

ADULT; AGED; ANGIOPLASTY; ARTICLE; ASSAY; BLOOD CLOTTING PARAMETERS; CARDIOVASCULAR DISEASE; CLINICAL EVALUATION; CONTROLLED STUDY; CORONARY STENT; DRUG EFFECT; DRUG POTENCY; FEMALE; HUMAN; HUMAN CELL; LOADING DRUG DOSE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; THROMBOCYTE FUNCTION;

ADULT; AGED; AGED, 80 AND OVER; ANGIOPLASTY, BALLOON, CORONARY; ASPIRIN; CARDIOVASCULAR DISEASES; DRUG INTERACTIONS; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; MALE; MIDDLE AGED; PLATELET AGGREGATION; PLATELET AGGREGATION INHIBITORS; PLATELET FUNCTION TESTS; PROTON PUMP INHIBITORS; STENTS; TICLOPIDINE;

EID: 78650174732     PISSN: 01602446     EISSN: None     Source Type: Journal    
DOI: 10.1097/FJC.0b013e3181f68209     Document Type: Article

References (51)

1. Laine L, Hennekens C. Proton pump inhibitor and clopidogrel interaction: fact or fiction? Am J Gastroenterol. 2010;105:34-41.
2. Ishizaki T, Horai Y. Review article: cytochrome P450 and the metabolism of proton pump inhibitors\emphasis on rabeprazole. Aliment Pharmacol Ther. 1999;13(Suppl 3):27-36.
3. Abelö A, Andersson TB, Antonsson M, et al. Stereoselective metabolism of omeprazole by human cytochrome P450 enzymes. Drug Metab Dispos. 2000;28:966-972. (Pubitemid 30612617)
4. Cattaneo M. P2Y12 receptor antagonists: a rapidly expanding group of antiplatelet agents. Eur Heart J. 2006;27:1010-1012.
5. Blume H, Donath F, Warnke A, et al. Pharmacokinetic drug interaction profiles of proton pump inhibitors. Drug Saf. 2006;29:769-784.
6. Humphries TJ, Merritt GJ. Review article: drug interactions with agents used to treat acid-related diseases. Aliment Pharmacol Ther. 1999; 13(Suppl 3):18-26.
7. Howden CW. Clinical pharmacology of omeprazole. Clin Pharmacokinet. 1991;20:38-49.
8. Andersson T, Miners JO, Veronese ME, et al. Identification of human liver cytochrome P450 isoforms mediating omeprazole metabolism. Br J Clin Pharmacol. 1993;36:521-530.
9. Andersson T, Hassan-Alin M, Hasselgren G, et al. Drug interaction studies with esomeprazole, the (S)-isomer of omeprazole. Clin Pharmacokinet. 2001;40:523-537.
10. Cheer SM, Prakash A, Faulds D, et al. Pantoprazole: an update of its pharmacological properties and therapeutic use in the management of acid-related disorders. Drugs. 2003;63:101-133.
11. Mega JL, Close SL, Wiviott SD, et al. Cytochrome p-450 polymorphisms and response to clopidogrel. N Engl J Med. 2009;360:354-362.
12. Simon T, Verstuyft C, Mary-Krause M, et al. French registry of acute ST-elevation and Non-ST-elevation myocardial infarction (FAST-MI) investigators. Genetic determinants of response to clopidogrel and cardiovascular events. N Engl J Med. 2009;360:363-375.
13. Giusti B, Gori AM, Marcucci R, et al. Relation of cytochrome P450 2C19 loss-of-function polymorphism to occurrence of drug-eluting coronary stent thrombosis. Am J Cardiol. 2009;103:806-811.
14. Trenk D, Hochholzer W, Fromm MF, et al. Cytochrome P450 2C19 681G. A polymorphism and high on-clopidogrel platelet reactivity associated with adverse 1-year clinical outcome of elective percutaneous coronary intervention with drug-eluting or bare-metal stents. J Am Coll Cardiol. 2008;51:1925-1934.
15. Sibbing D, Koch W, Gebhard D, et al. Cytochrome 2C19*17 allelic variant, platelet aggregation, bleeding events, and stent thrombosis in clopidogrel-treated patients with coronary stent placement. Circulation. 2010;121:512-518.
16. Gilard M, Arnaud B, Cornily JC, et al. Influence of omeprazole on the antiplatelet action of clopidogrel associated with aspirin: the randomized, double-blind OCLA (Omeprazole CLopidogrel Aspirin) study. J Am Coll Cardiol. 2008;51:256-260.
17. Zuern CS, Geisler T, Lutilsky N, et al. Effect of comedication with proton pump inhibitors (PPIs) on post-interventional residual platelet aggregation in patients undergoing coronary stenting treated by dual antiplatelet therapy. Thromb Res. 2010;125:e51-e54.
18. Sibbing D, Morath T, Stegherr J, et al. Impact of proton pump inhibitors on the antiplatelet effects of clopidogrel. Thromb Haemost. 2009;101:714-719.
19. Siller-Matula JM, Spiel AO, Lang IM, et al. Effects of pantoprazole and esomeprazole on platelet inhibition by clopidogrel. Am Heart J. 2009;157: e1-e5.
20. Neubauer H, Engelhardt A, Krü ger JC, et al. Pantoprazole does not influence the antiplatelet effect of clopidogrel\A whole blood aggregometry study following coronary stenting. J Cardiovasc Pharmacol. 2010;56:91-97.
21. Yun KH, Rhee SJ, Park HY, et al. Effects of omeprazole on the antiplatelet activity of clopidogrel. Int Heart J. 2010;51:13-16.
22. Mani H, Kirchmayr K, Klaffling C, et al. Influence of blood collection techniques on platelet function. Platelets. 2004;15:315-318.
23. Gremmel T, Steiner S, Seidinger D, et al. Comparison of methods to evaluate clopidogrel-mediated platelet inhibition after percutaneous intervention with stent implantation. Thromb Haemost. 2009;101:333-339.
24. Cattaneo M, Lecchi A, Zighetti ML, et al. Platelet aggregation studies: autologous platelet-poor plasma inhibits platelet aggregation when added to platelet-rich plasma to normalize platelet count. Haematologica. 2007; 92:694-697.
25. Linnemann B, Schwonberg J, Mani H, et al. Standardization of light transmittance aggregometry for monitoring antiplatelet therapy: an adjustment for platelet count is not necessary. J Thromb Haemost. 2008;6:677-683.
26. Siller-Matula JM, Panzer S, Jilma B. Reproducibility and standardized reporting of the vasodilator-stimulated phosphoprotein phosphorylation assay. Platelets. 2008;19:551-554.
27. Panzer S, Eichelberger B, Koren D, et al. Monitoring survival and function of transfused platelets in Bernard-Soulier syndrome by flow cytometry and a cone and plate(let) analyzer (Impact-R). Transfusion. 2007;47: 103-106.
28. Shenkman B, Matetzky S, Fefer P, et al. Variable responsiveness to clopidogrel and aspirin among patients with acute coronary syndrome as assessed by platelet function tests. Thromb Res. 2008;122:336-345.
29. Matetzky S, Fefer P, Shenkman B, et al. Effectiveness of reloading to overcome clopidogrel nonresponsiveness in patients with acute myocar-dial infarction. Am J Cardiol. 2008;102:524-529.
30. Matetzky S, Shenkman B, Guetta V, et al. Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction. Circulation. 2004;109: 3171-3175.
31. Price MJ, Endemann S, Gollapudi RR, et al. Prognostic significance of post-clopidogrel platelet reactivity assessed by a point-of-care assay on thrombotic events after drug-eluting stent implantation. Eur Heart J. 2008;29:992-1000.
32. Geisler T, Langer H, Wydymus M, et al. Low response to clopidogrel is associated with cardiovascular outcome after coronary stent implantation. Eur Heart J. 2006;27:2420-2425.
33. Frere C, Cuisset T, Quilici J, et al. ADP-induced platelet aggregation and platelet reactivity index VASP are good predictive markers for clinical outcomes in non-ST elevation acute coronary syndrome. Thromb Haemost. 2007;98:838-843.
34. Gurbel PA, Bliden KP, Guyer K, et al. Platelet reactivity in patients and recurrent events post-stenting: results of the PREPARE POST-STENTING study. J Am Coll Cardiol. 2005;46:1820-1826.
35. Gurbel PA, Bliden KP, Hiatt BL, et al. Clopidogrel for coronary stenting: response variability, drug resistance, and the effect of pretreatment platelet reactivity. Circulation. 2003;107:2908-2913.
36. Buonamici P, Marcucci R, Migliorini A, et al. Impact of platelet reactivity after clopidogrel administration on drug-eluting stent thrombosis. J Am Coll Cardiol. 2007;49:2312-2317.
37. van Werkum JW, van der Stelt CA, Seesing TH, et al. A head-to-head comparison between the verifynow P2Y12 assay and light transmittance aggregometry for monitoring the individual platelet response to clopidogrel in patients undergoing elective percutaneous coronary intervention. J Thromb Haemost. 2006;4:2516-2518.
38. Aleil B, Ravanat C, Cazenave JP, et al. Flow cytometric analysis of intraplatelet VASP phosphorylation for the detection of clopidogrel resistance in patients with ischemic cardiovascular diseases. J Thromb Haemost. 2005;3:85-92. (Pubitemid 41647119)
39. Marcucci R, Gori AM, Paniccia R, et al. Cardiovascular death and nonfatal myocardial infarction in acute coronary syndrome patients receiving coronary stenting are predicted by residual platelet reactivity to ADP detected by a point-of-care assay: a 12-month follow-up. Circulation. 2009;119:237-242.
40. Sibbing D, Braun S, Morath T, et al. Platelet reactivity after clopidogrel treatment assessed with point-of-care analysis and early drug-eluting stent thrombosis. J Am Coll Cardiol. 2009;53:849-856.
41. Siller-Matula JM, Christ G, Lang IM, et al. Multiple electrode aggregometry better predicts stent thrombosis than the VASP assay. J Thromb Haemost. 2010;8:351-359.
42. Bonello L, Paganelli F, Arpin-Bornet M, et al. Vasodilator-stimulated phosphoprotein phosphorylation analysis prior to percutaneous coronary intervention for exclusion of postprocedural major adverse cardiovascular events. J Thromb Haemost. 2007;5:1630-1636.
43. Cuisset T, Frere C, Quilici J, et al. High post-treatment platelet reactivity identified low-responders to dual antiplatelet therapy at increased risk of recurrent cardiovascular events after stenting for acute coronary syndrome. J Thromb Haemost. 2006;4:542-549.
44. Paniccia R, Antonucci E, Gori AM, et al. Different methodologies for evaluating the effect of clopidogrel on platelet function in high-risk coronary artery disease patients. J Thromb Haemost. 2007;5: 1839-1847.
45. O'Donoghue ML, Braunwald E, Antman EM, et al. Pharmacodynamic effect and clinical efficacy of clopidogrel and prasugrel with or without a proton-pump inhibitor: an analysis of two randomised trials. Lancet. 2009;374:989-997.
46. Rassen JA, Choudhry NK, Avorn J, et al. Cardiovascular outcomes and mortality in patients using clopidogrel with proton pump inhibitors after percutaneous coronary intervention or acute coronary syndrome. Circulation. 2009;120:2322-2329.
47. Ho PM, Maddox TM, Wang L, et al. Risk of adverse outcomes associated with concomitant use of clopidogrel and proton pump inhibitors following acute coronary syndrome. JAMA. 2009;301:937-944.
48. Gaglia MA Jr, Torguson R, Hanna N, et al. Relation of proton pump inhibitor use after percutaneous coronary intervention with drug-eluting stents to outcomes. Am J Cardiol. 2010;105:833-838.
49. Kwok CS, Loke YK. Meta-analysis: the effects of proton pump inhibitors on cardiovascular events and mortality in patients receiving clopidogrel. Aliment Pharmacol Ther. 2010;31:810-823.
50. Helft G, Osende JI, Worthley SG, et al. Acute antithrombotic effect of a front-loaded regimen of clopidogrel in patients with atherosclerosis on aspirin. Arterioscler Thromb Vasc Biol. 2000;20:2316-2321.
51. Siller-Matula JM, Haberl K, Prillinger K, et al. The effect of antiplatelet drugs clopidogrel and aspirin is less immediately after stent implantation. Thromb Res. 2009;123:874-880.